All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Key considerations when treating patients with newly diagnosed high-risk MM

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Saad Zafar Usmani, Levine Cancer Institute, Charlotte, US. He discussed key considerations when treating patients with newly diagnosed high-risk MM.

Usmani discusses differences in survival outcomes observed between standard- and intermediate-risk patients versus high-risk patients. Usmani suggests that future clinical trials should focus on high-risk patients with the aim to improve current patient prognosis.

 

Share: